At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNRX Quoin Pharmaceuticals
Trading 08-27 09:41:04 EDT
5.18
+0.00
0.00%
High5.18Low5.18Vol57.00
Open5.18D1 Closing5.18Amplitude0.00%
Mkt Cap10.40MTradable Cap7.42MTotal Shares2.01M
T/O293.40T/O Rate0.00%Tradable Shares1.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quoin Pharmaceuticals Shareholders Approve Governance and Compensation Changes
TIPRANKS  ·  08-21
Quoin Pharmaceuticals Shareholders Approve Governance and Compensation Changes
Quoin Pharmaceuticals Shareholders Approved 401(k) Matching Contribution Changes at Annual Meeting
Reuters  ·  08-21
Quoin Pharmaceuticals Shareholders Approved 401(k) Matching Contribution Changes at Annual Meeting
Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)
TIPRANKS  ·  08-16
Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)
Quoin Pharmaceuticals Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Quoin Pharmaceuticals Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary
Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate
Benzinga Earnings  ·  08-14
Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate
Press Release: Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Dow Jones  ·  08-14
Press Release: Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals Ltd Expected to Post a Loss of $1.61 a Share - Earnings Preview
Reuters  ·  08-12
Quoin Pharmaceuticals Ltd Expected to Post a Loss of $1.61 a Share - Earnings Preview
Quoin Pharmaceuticals Updates Financial Calendar, Sets Q2 Results Release and Corporate Update
Reuters  ·  08-07
Quoin Pharmaceuticals Updates Financial Calendar, Sets Q2 Results Release and Corporate Update
Quoin Pharmaceuticals Ltd Expected to Post a Loss of $1.61 a Share - Earnings Preview
Reuters  ·  08-03
Quoin Pharmaceuticals Ltd Expected to Post a Loss of $1.61 a Share - Earnings Preview
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops
Simply Wall St.  ·  07-16
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops
Maxim Group Remains a Buy on Quoin Pharmaceuticals (QNRX)
TIPRANKS  ·  07-10
Maxim Group Remains a Buy on Quoin Pharmaceuticals (QNRX)
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
TIPRANKS  ·  07-09
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
Quoin Pharma Wins FDA IND Clearance for Qrx003 in Peeling Skin Syndrome
Reuters  ·  07-09
Quoin Pharma Wins FDA IND Clearance for Qrx003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Announces Annual Shareholder Meeting
Reuters  ·  07-07
Quoin Pharmaceuticals Announces Annual Shareholder Meeting
Quoin Pharmaceuticals receives notice of allowance for QRX003 patent
TIPRANKS  ·  06-30
Quoin Pharmaceuticals receives notice of allowance for QRX003 patent
Quoin Pharma Wins US Notice of Allowance for Netherton Syndrome Combination-treatment Patent Application
Reuters  ·  06-30
Quoin Pharma Wins US Notice of Allowance for Netherton Syndrome Combination-treatment Patent Application
NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am
Reuters  ·  06-24
NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am
Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40
THOMSON REUTERS  ·  06-23
Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40
Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval
MT Newswires Live  ·  06-23
Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval
Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug
Reuters  ·  06-23
Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug

Introduction

Company Name.
Quoin Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
Issue price:
--